Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson
Portfolio Pulse from Avi Kapoor
Jim Cramer, on CNBC's 'Mad Money Lightning Round,' provided various stock recommendations including holding ConocoPhillips, buying Marvell Technology, and not selling McKesson. He labeled Rhythm Pharmaceuticals as a speculative play, advised waiting for a lower price on Lam Research, and recommended selling Aspen Aerogels for profit. Cramer was cautious about Enovix due to lack of profitability and suggested a staggered buying approach for PNC Financial Services. He also mentioned Vale S.A. is too low to sell.
April 19, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cramer recommended selling Aspen Aerogels for profit after a 1.7% drop to $14.82.
Cramer's sell recommendation for Aspen Aerogels, especially after a significant gain, suggests a bearish short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Cramer was cautious about Enovix due to lack of profitability, with shares dipping 9.4% to $6.01.
Cramer's caution on Enovix due to its lack of profitability suggests a bearish short-term outlook, aligning with the significant recent drop.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Jim Cramer recommended holding ConocoPhillips shares, which fell 0.4% to $127.81.
Cramer's endorsement to hold suggests a neutral short-term outlook, potentially stabilizing the stock after a minor decline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Cramer advised not selling McKesson Corporation, which slipped 1.4% to $518.81.
Cramer's recommendation not to sell McKesson suggests a neutral to positive short-term outlook, despite a recent price decline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Cramer mentioned Vale S.A. is too low to sell, with shares falling 0.1% to $11.84.
Cramer's view that Vale is too low to sell suggests a neutral short-term outlook, implying the stock may have bottomed out or is close to doing so.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Cramer suggests waiting for a lower price on Lam Research, which fell 2.6% to $888.92.
Cramer's advice to wait for a lower price on Lam Research indicates a bullish outlook, suggesting the current dip may offer a buying opportunity.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Cramer recommended buying Marvell Technology, especially if it drops under $60, after a 1.9% decline to $65.24.
Cramer's buy recommendation, particularly on dips, indicates a bullish short-term outlook despite the recent drop.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Cramer suggested a staggered buying approach for PNC Financial Services, which gained 0.4% to $147.89.
Cramer's staggered buying recommendation indicates a positive short-term outlook for PNC Financial Services, especially after a slight gain.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Rhythm Pharmaceuticals is considered a speculative play by Cramer, with shares down 0.9% to $38.11.
Labeling Rhythm Pharmaceuticals as a speculative play suggests potential for high reward despite recent decline, indicating a positive short-term outlook.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70